Mode
Text Size
Log in / Sign up

Graves' disease is associated with lower bone mineral density and higher serum calcium levelsGraves' disease is linked to lower bone mineral density

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that Graves' disease is associated with lower bone mineral density and higher serum calcium levels.

This meta-analysis involving 3,643 patients evaluates the impact of Graves' disease (GD) on bone health. The analysis found that GD patients have significantly lower bone mineral density compared to controls (Mean Difference = -0.09; 95% CI [-0.10, -0.07], P < 0.001). Additionally, a statistically significant increase in serum calcium was observed in the GD group (Standard Mean Difference = 0.37; 95% CI [0.18, 0.57], P = 0.023).

A secondary cross-sectional analysis of 42,374 individuals in the UK Biobank identified a statistically significant association between hyperthyroidism and bone mineral density at the ribs (P < 0.05). However, no significant differences were observed for bone mineral density at the lumbar spine or femoral neck in this larger cohort.

The authors note several limitations, including high heterogeneity in the meta-analysis (I2 = 92.1%) and a limited number of confirmed GD cases in the UK Biobank, which required a broader definition of hyperthyroidism for that analysis. These factors contribute to lower certainty regarding the widespread extent of bone mineral density reduction. Clinically, these findings suggest a risk-stratified approach to bone health screening for patients with Graves' disease, particularly for high-risk groups such as postmenopausal women or older adults.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the skeletal impact of Graves' disease. While previous coverage has focused on treatment preferences (antithyroid drugs), surgical interventions (ultrasound-guided thermal ablation), and adjunctive therapies (TCM combinations) for managing Graves' disease, this study provides evidence regarding the specific association between the condition and bone mineral density.

Living with Graves' disease can affect more than just your thyroid. New research suggests that this condition is linked to lower bone mineral density, which is the amount of minerals like calcium and phosphorus in your bones. This matters because healthy bones are essential for mobility and preventing fractures as we age.

A large review of over 3,600 patients found that those with Graves' disease had lower bone mineral density compared to others. The study also noted higher levels of serum calcium in these patients. However, a separate look at over 42,000 people showed that while some areas like the ribs showed changes, other areas like the spine and hip did not show clear differences.

Because the results were mixed across different studies, experts say we cannot say for certain how much the disease impacts everyone's bones. The evidence is currently suggestive rather than definitive. Because of this uncertainty, doctors may choose to focus bone screenings on specific groups who might be at higher risk, such as older adults or postmenopausal women.

What this means for you:
Graves' disease is linked to lower bone density, but the impact varies depending on the person and location.

Common questions

Does Graves' disease affect bone health?

Research suggests that people with Graves' disease have lower bone mineral density compared to others. While the evidence is not definitive for everyone, it shows a link between the condition and less mineral content in the bones.

Are there different effects on different parts of the body?

The study found that while some areas like the ribs showed a significant link to hyperthyroidism, other areas like the lumbar spine and femoral neck did not show significant differences in bone mineral density.

Who is most at risk for bone issues with this condition?

Because results vary, doctors may use a risk-stratified approach. This means they might prioritize bone screenings for specific groups, such as postmenopausal women, older adults, or individuals with a low body mass index.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
ObjectiveTo investigate the association between Graves’ disease (GD) and bone mineral density by integrating a meta-analysis with a large-scale cross-sectional analysis in the UK Biobank.MethodsWe systematically searched PubMed, Web of Science, and Cochrane Library for cohort and cross-sectional studies. The pooled findings were then examined in the UK Biobank using multivariable linear regression models with adjustment for age, BMI, lifestyle factors, vitamin D, calcium, and sex.ResultsThe meta-analysis (14 studies, 3,643 participants) showed that GD patients had significantly lower bone mineral density than controls (Mean Difference = −0.09, 95% CI [−0.10, −0.07], P < 0.001) and higher serum calcium (Standard Mean Difference = 0.37, 95% CI [0.18, 0.57], P = 0.023). However, substantial between-study heterogeneity was observed (I2 = 92.1%), indicating considerable variation across studies. Meta-regression and subgroup analyses identified postmenopausal women, older age (>50 years), and lower BMI as key factors amplifying the association. In the UK Biobank (n = 42374), after rigorous adjustment for all covariates, the association was substantially attenuated and remained statistically significant only at the ribs (P < 0.05), while other skeletal sites, including the lumbar spine and femoral neck, showed no significant differences.ConclusionThis dual-evidence approach provides suggestive, rather than definitive, evidence that GD is associated with reduced BMD. The meta-analysis suggested widespread BMD reductions in GD patients. However, due to the limited number of confirmed GD cases, the fully adjusted UK Biobank analysis adopted a broader exposure definition of hyperthyroidism and observed a nominally statistically significant association only at the ribs, with no significant differences detected at other skeletal sites. Given the limited replication of the meta-analysis findings and the high heterogeneity observed in the meta-analysis, we advocate for a risk-stratified approach to BMD screening that prioritizes postmenopausal women, older adults, and individuals with low BMI, rather than routine screening for all GD patients. These findings underscore the need for prospective studies with standardized protocols to clarify the skeletal impact of GD and to guide evidence-based bone health management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.